Company Monitoring Page for Novartis

latest headlines for company on cafepharma

From no drugs to 3: Patients with spinal muscular atrophy now face hard choices
BioPharma Dive
Mon, 10/5/20 - 11:39 pm
Tags:
SMA, spinal muscular atrophy, Novartis, Zolgensma, Spinraza, Roche, Evrysdi
Amgen Highlights Long-Term Aimovig Data for Episodic Migraine
BioSpace
Mon, 10/5/20 - 11:43 am
Tags:
Amgen, Novartis, Aimovig, migraines, episodic migraines
Novartis, Amgen and Mallinckrodt used aggressive price hikes to meet sales goals, congressional probe finds
Fierce Pharma
Thu, 10/1/20 - 11:29 am
Tags:
congress, drug pricing, Novartis, Amgen, Mallinckrodt
Novartis sells $2.1B in bonds to increase access to its drugs in disadvantaged countries
Beckers Hospital Review
Thu, 09/24/20 - 10:28 am
Tags:
Novartis, bonds, access
FDA sets back Novartis plans to expand use of SMA gene therapy
BioPharma Dive
Wed, 09/23/20 - 10:39 am
Tags:
Novartis, SMA, gene therapy, Zolgensma, clinical trials, FDA
Bristol, Amgen, Teva CEOs among execs to testify at House drug pricing hearings next week
Fierce Pharma
Tue, 09/22/20 - 10:21 pm
Tags:
drug pricing, regulatory, Celgene, Bristol-Myers Squibb, Teva Pharmaceutical, Amgen, Novartis, Mallinckrodt, AbbVie, US Congress
OptumRx's 3 recently approved drugs to watch
Beckers Hospital Review
Tue, 09/22/20 - 10:15 pm
Tags:
FDA, Kite Pharma, Tecartus, Novartis, Kesimpta, MorphoSys, Monjuvi, OptumRx
Sandoz working to overcome barriers to greater biosimilars uptake in US
Biopharma Reporter
Mon, 09/21/20 - 10:55 am
Tags:
Sandoz, biosimilars, Novartis
ESMO: Novartis parses long-awaited survival data for breast cancer blockbuster hopeful Piqray
Fierce Pharma
Sat, 09/19/20 - 09:12 pm
Tags:
ESMO, Novartis, breast cancer, Piqray, Faslodex, AstraZeneca
BioNTech acquires German manufacturing site to boost COVID-19 vaccine production
Biopharma Reporter
Thu, 09/17/20 - 10:48 am
Tags:
BioNTech, Novartis, Germany, vaccines, MRNA, COVID-19
Novartis says Beovu matched rival Eylea in visual acuity in eye disease
Pharma Live
Mon, 09/14/20 - 10:41 am
Tags:
Novartis, Beovu, Eylea, Regeneron, diabetic macular edema, clinical trials
After Novartis left, Boehringer bets up to $500M on the field of prescription smartphone app
Endpoints
Fri, 09/11/20 - 10:44 am
Tags:
Boehringer Ingelheim, digital therapeutics, Click Therapeutics, mobile apps, Novartis
Novartis, Roche fined $526M in France for alleged Lucentis marketing missteps
Fierce Pharma
Wed, 09/9/20 - 10:59 am
Tags:
Novartis, Roche, France, Lucentis, anti-competitive scheme
Big pharma spinouts grow up
EP Vantage
Tue, 09/8/20 - 10:53 am
Tags:
Big Pharma, spinoffs, Merck KGaA, Pfizer, GSK, Novartis, Roche, Sanofi, JNJ, AstraZeneca
In the footsteps of AstraZeneca, Novartis commits to carbon-neutral supply chain by 2030
Endpoints
Tue, 09/1/20 - 11:06 am
Tags:
AstraZeneca, Novartis, carbon neutrality, environmental concerns
Novartis targets Alexion's fiefdom after showing PNH patients can safely switch from Soliris
Fierce Biotech
Mon, 08/31/20 - 08:54 pm
Tags:
Novartis, clinical trials, PNH, Alexion Soliris, LNP023
ESC: Novartis' Entresto racks up a heart failure study win—but it's a mixed one
Fierce Pharma
Mon, 08/31/20 - 10:20 am
Tags:
Novartis, Entresto, ESC, heart failure
Novartis puts spokesceleb Cyndi Lauper in host chair for life-with-psoriasis podcast
Fierce Pharma
Sat, 08/29/20 - 11:38 pm
Tags:
Novartis, podcasts, psoriasis, celebrity endorsements, Cosentyx
Novartis’ ABL001 meets primary endpoint of phase 3 chronic myeloid leukemia study
Pharmaceutical Business Review
Thu, 08/27/20 - 11:01 am
Tags:
Novartis, asciminib, ABL001, clinical trials, chronic myeloid leukemia
Blow for Novartis as PD-1 drug spartalizumab flunks trial
Pharmaforum
Sun, 08/23/20 - 06:28 pm
Tags:
Novartis, clinical trials, spartalizumab, skin cancer

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.